RET-Altered Cancers: Recent Research Overview

The following scientific articles were selected to give an overview of research topics related to RET-altered cancers. They are focused on more recent research and will be updated periodically.

Recent Research on Cancers with Alterations in the RET Gene: An Overview

RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives

Hyper–Sensitive? Targeted Therapy With a Primed Immune System

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape

Genomic landscape of 891 RET fusions detected across diverse solid tumor types

LIBRETTO-001 Trial Articles: Selpercatinib for Lung and Thyroid Cancer

Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

ARROW Trial Articles: Pralsetinib for Lung and Thyroid Cancer

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

Selpercatinib vs. Pralsetinib: A Comparison of RET Inhibitors

A major difference in RET inhibition found between pralsetinib and selpercatinib

Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations

Efficacy of Selpercatinib (Retevmo) and Pralsetinib (Gavreto) in RET-driven Cancers Beyond Lung and Thyroid

Tumour-agnostic efficacy and safety of selpercatinib in patients with RETfusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

Pan-cancer efficacy of pralsetinib in patients with RETfusion–positive solid tumors from the phase 1/2 ARROW trial

Real World Data and Evidence on RET-Altered Cancers

RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer

Emerging Treatment Options in the Management of Resistance to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

Emerging Treatment Options in the Management of Resistance to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

Detecting RET Fusions

A Performance Comparison of Commonly Used Assays to Detect RET Fusions

 

RET Inhibitor Side Effects

Hyper–Sensitive? Targeted Therapy With a Primed Immune System

Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase

Next-Generation RET Inhibitors

Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer

Abstract 5363: The preclinical selectivity and activity of APS03118, a highly selective and potent next-generation RET inhibitor

The next-generation RET inhibitor TPX-0046 is active in drug-resistant and naïve RET-driven cancer models

RET Kinase Inhibitors for RET-Altered Thyroid Cancers

RET kinase inhibitors for RET-altered thyroid cancers

 

Oligo Progression (Limited Progression) in Fusion+ Lung Cancers

Update on Treatment Tactics in ALK/ROS/RET-Rearranged NSCLC